Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher,

Slides:

Advertisements

Similar presentations

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.

Advertisements

Bortezomib Induction and Maintenance Treatment Improves Survival in Patients with Newly Diagnosed Multiple Myeloma: Extended Follow-Up of the HOVON-65/GMMG-HD4.

A randomized trial comparing standard versus high-dose daunorubicin induction in patients with acute myeloid leukemia by Je-Hwan Lee, Young-Don Joo, Hawk.

Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,

GEM2005MAS65 Trial: Bortezomib-Based Maintenance Increases CR Rate and PFS in Elderly Patients With Newly Diagnosed Multiple Myeloma Slideset on: Mateos.

Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation by Surbhi Shah, Faye L. Norby, Yvonne.

Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance.

Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival by Kai-Da Wu, Lisa.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

One giant leap for pediatric AMKL

by Thomas Rasmussen, Linda Jensen, Lone Honoré, and Hans Erik Johnsen

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk.

Darwinian evolution and tiding clones in multiple myeloma

Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system by.

SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group by Yok-Lam Kwong, Won Seog Kim, Soon Thye.

by Jayesh Mehta Blood Volume 112(2): July 15, 2008

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Primary testicular lymphoma

Early autologous stem cell transplantation for chronic lymphocytic leukemia: long-term follow-up of the German CLL Study Group CLL3 trial by Peter Dreger,

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone by Patrizia Tosi, Elena.

Early platelet count kinetics has prognostic value in lower-risk myelodysplastic syndromes by Raphael Itzykson, Simon Crouch, Erica Travaglino, Alex Smith,

Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma by Angela Dispenzieri,

Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group.

A multiple myeloma classification system that associates normal B-cell subset phenotypes with prognosis by Julie Støve Bødker, Rasmus Froberg Brøndum,

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p by James I. Barnes, Vasu Divi,

Natural killer receptor ligand expression on acute myeloid leukemia impacts survival and relapse after chemotherapy by Sara Mastaglio, Eric Wong, Travis.

Quantifying the risk of multiple myeloma from symptoms reported in primary care patients: a large case–control study using electronic records by Elizabeth.

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study by C. Madsen, M. R. Clausen, T. L. Plesner,

Mintu P. Turakhia et al. JACEP 2016;2:

Genetic heterogeneity of cytogenetically normal AML with mutations of CEBPA by Nikola P. Konstandin, Friederike Pastore, Tobias Herold, Annika Dufour,

Validation of the United Kingdom copy-number alteration classifier in 3239 children with B-cell precursor ALL by Lina Hamadeh, Amir Enshaei, Claire Schwab,

Prabhat Kumar et al. JACEP 2016;j.jacep

Effects of Blood Transfusion on Cause-Specific Late Mortality After Coronary Artery Bypass Grafting—Less Is More Thomas A. Schwann, MD, Joseph R. Habib,

Retrospective analysis of capillary hemoglobin recovery in nearly 1 200 000 blood donor returns by Pia Niittymäki, Mikko Arvas, Antti Larjo, Pirkko Mattila,

A 4-lncRNA scoring system for prognostication of adult myelodysplastic syndromes by Chi-Yuan Yao, Ching-Hsuan Chen, Huai-Hsuan Huang, Hsin-An Hou, Chien-Chin.

Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Dharshan Sivaraj, Michael.

Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group by Tao Wu, Yong Yang, Su-Yu.

by Kaiwen Chen, Matthew P. Cheng, Sarah P

by Hassan Awada, Yasunobu Nagata, Abhinav Goyal, Mohammad F

by Fumiko Chino, Arif H. Kamal, Junzo Chino, and Thomas W. LeBlanc

Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk.

Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia by Thai Hoa Tran, Marian.

Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy by Zimu Gong, L. Jeffrey Medeiros, Jorge.

Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma by Sham Mailankody, Dickran Kazandjian, Neha Korde,

Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed/refractory patients by Cirino Botta, Domenico Ciliberto,

Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors by Manabu Wakamatsu, Seitaro Terakura,

Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 study by Marius Flasinski, Kira Scheibke, Martin Zimmermann,

Plasma biomarker concentrations between study groups.

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Malglycemia is associated with poor outcomes in pediatric and adolescent hematopoietic stem cell transplant patients by Jenna Sopfe, Laura Pyle, Amy K.

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

by H. Ddungu, M. Waiswa, R. Kruisselbrink, P. Kagoma, and M. Crowther

Health outcomes and services in children with sickle cell trait, sickle cell anemia, and normal hemoglobin by Sarah L. Reeves, Hannah K. Jary, Jennifer.

Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma by Tilmann Bochtler, Maximilian Merz,

Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation by Yoshihiro Inamoto, Tomohiro Matsuda, Ken Tabuchi,

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

by David Deambrosis, Su Han Lum, Ryan M

PD-L1 and tumor-associated macrophages in de novo DLBCL

Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015 by Evaren E. Page, Johanna A.

Increase of physical activity over time associated with lower HF risk

Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables by Andrew W. Roberts, Shuo Ma, Thomas J.

Impact of age on clinical risk scores in follicular lymphoma

MiR-520d-3p is an independent positive prognostic factor in ovarian cancer. miR-520d-3p is an independent positive prognostic factor in ovarian cancer.

Pracinostat plus azacitidine in older patients with newly diagnosed acute myeloid leukemia: results of a phase 2 study by Guillermo Garcia-Manero, Yasmin.

Secretory status of monoclonal immunoglobulin is related to the outcome of patients with myeloma: a retrospective study by Xiao-Qi Qin, Gang An, Zeng-Jun.

Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib by Chung H. Kok, David T.

How I treat T-cell acute lymphoblastic leukemia in adults

Presentation transcript:

Prognostic significance of cytogenetic heterogeneity in patients with newly diagnosed multiple myeloma by Maximilian Merz, Anna Jauch, Thomas Hielscher, Tilmann Bochtler, Stefan Olaf Schönland, Anja Seckinger, Dirk Hose, Uta Bertsch, Kai Neben, Marc Steffen Raab, Jens Hillengass, Hans Salwender, Igor Wolfgang Blau, Hans-Walter Lindemann, Ingo G. H. Schmidt-Wolf, Christof Scheid, Mathias Haenel, Katja C. Weisel, and Hartmut Goldschmidt BloodAdv Volume 2(1):1-9 January 9, 2018 © 2017 by The American Society of Hematology

Maximilian Merz et al. Blood Adv 2018;2:1-9 © 2017 by The American Society of Hematology

Outcome of patients with or without high-risk aberrations. Outcome of patients with or without high-risk aberrations. (A) +1q21: blue, no +1q21; red, subclone +1q21; green, main clone +1q21. (B) −17p: blue, no −17p; red, subclone −17p; green, main clone −17p. (C) ±MYC: blue, no ±MYC; red, subclone ± MYC; green, main clone ± MYC. Maximilian Merz et al. Blood Adv 2018;2:1-9 © 2017 by The American Society of Hematology

Outcome of patients with (red) or without (blue) subclones. Outcome of patients with (red) or without (blue) subclones. (A) Entire cohort, (B) patients with standard-risk, and (C) high-risk main clone aberration. Maximilian Merz et al. Blood Adv 2018;2:1-9 © 2017 by The American Society of Hematology

Outcome of high-risk patients. Outcome of high-risk patients. (A) Standard- and (B) high-risk patients. Bortezomib arm: purple, no subclone; red, with subclone. Thalidomide arm: green, no subclone; blue, with subclone. Colored numbers below the plots represent uncensored patients at the respective time point. Maximilian Merz et al. Blood Adv 2018;2:1-9 © 2017 by The American Society of Hematology

Forest plots from univariate analysis. Forest plots from univariate analysis. PFS (upper panel) and OS (lower panel) for the entire cohort and standard- and high-risk patients. Green, all patients; red, PAD arm; blue, VAD arm. CI, confidence interval; HR, hazard ratio; VAD, vincristine, Adriamycin, and dexamethasone. Maximilian Merz et al. Blood Adv 2018;2:1-9 © 2017 by The American Society of Hematology